Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study
Simple Summary
Williet, N.; Petrillo, A.; Roth, G.; Ghidini, M.; Petrova, M.; Forestier, J.; Lopez, A.; Thoor, A.; Weislinger, L.; De Vita, F.; Taieb, J.; Phelip, J.M. Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. Cancers 2021, 13, 2797. https://doi.org/10.3390/cancers13112797
Williet N, Petrillo A, Roth G, Ghidini M, Petrova M, Forestier J, Lopez A, Thoor A, Weislinger L, De Vita F, Taieb J, Phelip JM. Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. Cancers. 2021; 13(11):2797. https://doi.org/10.3390/cancers13112797
Chicago/Turabian StyleWilliet, Nicolas, Angelica Petrillo, Gaël Roth, Michele Ghidini, Mila Petrova, Julien Forestier, Anthony Lopez, Audrey Thoor, Lucie Weislinger, Ferdinando De Vita, Julien Taieb, and Jean M. Phelip. 2021. "Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study" Cancers 13, no. 11: 2797. https://doi.org/10.3390/cancers13112797